← Back to Search

Contrast Enhanced Ultrasound for Liver Cirrhosis and Acute Kidney Injury

N/A

Waitlist Available

Research Sponsored by University of Virginia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cirrhosis of liver

Age >18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 0 - 48 hours

Awards & highlights

Study Summary

This trial will test whether contrast-enhanced ultrasound can help diagnose the cause of acute kidney injury in patients with cirrhosis, which would help doctors better treat the condition.

Who is the study for?

This trial is for adults over 18 with liver cirrhosis and acute kidney injury, hospitalized at the University of Virginia Medical Center. It's not for pregnant or breastfeeding individuals, those on hemodialysis, with certain heart or lung conditions, allergies to Definity®, or a history of liver/kidney transplant.Check my eligibility

What is being tested?

The study tests if Contrast Enhanced Ultrasound (CEU) can help tell apart different causes of kidney injury in patients with liver cirrhosis by measuring changes in renal blood flow after volume expansion and specific treatments.See study design

What are the potential side effects?

Potential side effects from the Definity® contrast agent used in CEU may include allergic reactions, headache, nausea, altered taste sensation, warmth feeling during injection. Serious side effects are rare but could involve heart or breathing problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have cirrhosis of the liver.

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 - 48 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 - 48 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 - 48 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To assess the utility of monitoring of RBF using CEU in management of AKI in patients with liver cirrhosis.

Secondary outcome measures

Pattern of blood flow distribution in the kidney in different cases of AKI

Trial Design

1Treatment groups

Experimental Treatment

Group I: prerenal AKi, acute tubular necrosis and hepatorenal syndromeExperimental Treatment1 Intervention

All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor

753 Previous Clinical Trials

1,245,006 Total Patients Enrolled

Media Library

prerenal AKi, acute tubular necrosis and hepatorenal syndrome Clinical Trial Eligibility Overview. Trial Name: NCT02147470 — N/A

Liver Cirrhosis and Acute Kidney Injury Research Study Groups: prerenal AKi, acute tubular necrosis and hepatorenal syndrome

Liver Cirrhosis and Acute Kidney Injury Clinical Trial 2023: prerenal AKi, acute tubular necrosis and hepatorenal syndrome Highlights & Side Effects. Trial Name: NCT02147470 — N/A

prerenal AKi, acute tubular necrosis and hepatorenal syndrome 2023 Treatment Timeline for Medical Study. Trial Name: NCT02147470 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent have other investigations investigated this treatment?

"Currently, there is one Phase 3 and eighteen other clinical trials investigating this treatment. Most of the research is located in Philadelphia, Pennsylvania yet a total 26 medical sites are hosting these experiments."

Answered by AI

How many patients are participating in this research endeavor?

"This study is no longer accepting volunteers as the trial was last updated on May 21st, 2014. If you are still seeking to participate in clinical trials, there are currently 1258 studies involving kidney diseases and 19 research programs looking for this specific treatment that remain open."

Answered by AI

To what illness does this treatment typically bring relief?

"This therapy is capable of treating echocardiography, cardiovascular illnesses, and diagnostic imaging."

Answered by AI

Are there still vacancies in this trial for participants?

"The trial, which was originally published in February 2013 and modified last May, is not open to participants at this time. However, clinicaltrials.gov supplies a list of 1277 other trials that are currently accepting volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study

Kambiz Kalantarinia 2013. "Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02147470.

All > Fibrosis > Virginia